Directory
>
Anthony Coyle
Anthony Coyle
President, Head of Research and Development | Repertoire Immune Medicines
Cambridge, Massachusetts, United States
Anthony Coyle
Summary
Dr. Anthony Coyle is a distinguished immunologist and biotech entrepreneur with over 25 years of experience in drug discovery and development. He currently serves as the President and Head of Research and Development at Repertoire Immune Medicines, where he leads innovative research in immune therapies. Previously, he founded Pandion Therapeutics, successfully raising $58 million in a Series A funding round to advance treatments for autoimmune disorders. His leadership roles at Pfizer and Medimmune have significantly shaped therapeutic innovation, including the development of key compounds for respiratory and autoimmune diseases. Dr. Coyle is also a prolific author with over 200 peer-reviewed publications and holds numerous patents. He is dedicated to advancing collaborative approaches in drug development and actively participates in scientific advisory boards. His global speaking engagements reflect his commitment to sharing knowledge in immunology and drug development.
Anthony Coyle
Work Experience
President, Head of Research and Development at
Repertoire Immune Medicines
September 2020 - Present
Chief Executive Officer and Founder at
Pandion Therapeutics, Inc.
July 2017 - July 2019
Senior Vice President and CSO: Centers for Therapeutic Innovation at
Pfizer, Inc.
July 2010 - July 2017
VP, Global Head, Inflammation Biologics at
MedImmune
January 2007 - May 2010
Head, Respiratory Inflammation and Autoimmune Research Biology at
MedImmune
January 2004 - February 2006
Director, Inflammation Biology at
Takeda Oncology
January 1997 - May 2004
scientist at
Ciba
January 1992 - January 1996
Research Scientist at
Glaxo Institute For Molecular Biology
January 1993 - December 1995
Post Doctorial Research Assistant at
National Jewish Centre For Immunology And Respiratory Medicine
January 1990 - December 1992
Post Doctorial Assistant at
Institut Pasteur
January 1989 - December 1990
Anthony Coyle
Education
January 1986 - January 1989
King's College London, Bsc Honours
January 1982 - January 1986
Frequently Asked Questions about Anthony Coyle
What is Anthony Coyle email address?
Anthony Coyle's primary email address is ******@repertoire.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Anthony Coyle work for?
Anthony Coyle is a President, Head of Research and Development at Repertoire Immune Medicines.
Where Anthony Coyle graduated from?
Anthony Coyle holds a degree in Pharmacology from King's College London.
How can I directly contact Anthony Coyle?
To contact Anthony Coyle directly, you can use the email address ******@repertoire.com. Complete contact information is available upon registration with Muraena.
Who is Anthony Coyle?
Dr. Anthony Coyle is a distinguished immunologist and biotech entrepreneur with over 25 years of experience in drug discovery and development. He currently serves as the President and Head of Research and Development at Repertoire Immune Medicines, where he leads innovative research in immune therapies. Previously, he founded Pandion Therapeutics, successfully raising $58 million in a Series A funding round to advance treatments for autoimmune disorders. His leadership roles at Pfizer and Medimmune have significantly shaped therapeutic innovation, including the development of key compounds for respiratory and autoimmune diseases. Dr. Coyle is also a prolific author with over 200 peer-reviewed publications and holds numerous patents. He is dedicated to advancing collaborative approaches in drug development and actively participates in scientific advisory boards. His global speaking engagements reflect his commitment to sharing knowledge in immunology and drug development.
Anthony`s contact details
******@repertoire.com
*************@pfizer.com
******@medimmune.com
Colleagues
Vice President Human Resources
Vice President Finance
Senior Vice President, Protein Engineering and Molecular Sciences
Chief Business Officer